Are BTK and PLCG2 mutations required and adequate for ibrutinib resistance in chronic lymphocytic leukemia?Venetoclax is probably the greatest possibilities in this case, which include sufferers with higher-hazard genomic aberrations. The drug was previously verified helpful and Secure in several period I-II trials, in patients who had Beforehand o